Faldaprevir

N/A

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameFaldaprevir
Drug Alias NameFaldaprevirum法达瑞韦福达瑞韦BI-21335BI-201335
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsRenal InsufficiencyLiver CirrhosisHepatitis C, Chronic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[28] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgCatalent Pharma SolutionsBoehringer Ingelheim International Gmbh +[4] 
Active IndicationsN/A
Inactive IndicationsRenal InsufficiencyLiver CirrhosisHepatitis C, Chronic +[5] 

Other Information

ATC CodeJ05AP04
Related LinksWikipediaKEGG